Latest News

Zasocitinib Demonstrates Superiority vs Placebo and Apremilast in Phase 3 Plaque Psoriasis Trials
Zasocitinib Demonstrates Superiority vs Placebo and Apremilast in Phase 3 Plaque Psoriasis Trials

December 18th 2025

Zasocitinib showed significant efficacy in treating moderate-to-severe plaque psoriasis, outperforming placebo and apremilast in pivotal phase 3 trials.

Comorbidity Screening and Holistic Care in Hidradenitis Suppurativa, for Primary Care Clinicians / image credit ©grafixme/stock.adobe.com
Hidradenitis Suppurativa: A Comprehensive Care Plan for Primary Care

December 18th 2025

Rezpegaldesleukin Demonstrates Proof of Concept in Phase 2b Trial for Severe Alopecia Areata
Rezpegaldesleukin Demonstrates Proof of Concept in Phase 2b Trial for Severe Alopecia Areata

December 17th 2025

 Hidradenitis Suppurativa Essentials for Primary Care: When to Suspect, Initial Therapy, and When to Refer / image credit ©grafixme/stock.adobe.com
Hidradenitis Suppurativa Essentials for Primary Care: When to Suspect, Initial Therapy, and When to Refer

December 17th 2025

Chronic Skin Disease Linked to Wide Range of Addictive Behaviors in Large Pan-European Study / image credit ©Nataliia/stock.adobe.com
Chronic Skin Disease Linked to Wide Range of Addictive Behaviors in Pan-European Study

December 16th 2025

Latest CME Events & Activities
© 2025 MJH Life Sciences

All rights reserved.